It Is Time to Determine Tocilizumab's Place in Coronavirus Disease 2019 (COVID-19)
Clin Infect Dis
.
2022 Feb 11;74(3):560-562.
doi: 10.1093/cid/ciab480.
Authors
Klopfenstein Timothée
1
,
Aurélie Gerazime
2
,
Marc Puyraveau
2
,
N'dri Juliette Kadiane-Oussou
1
,
Vincent Gendrin
1
,
Souheil Zayet
1
Affiliations
1
Infectious Disease Department, Nord Franche-Comté Hospital, Trevenans, France.
2
Methodology Unit, Clinical Investigation Center, INSERM 1431, Jean-Minjoz University Hospital, Besançon, France.
PMID:
34036334
PMCID:
PMC8194799
DOI:
10.1093/cid/ciab480
No abstract available
Publication types
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
COVID-19 Drug Treatment*
Humans
SARS-CoV-2
Substances
Antibodies, Monoclonal, Humanized
tocilizumab